Theravance Biopharma (TBPH) News Today → [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad) Free TBPH Stock Alerts $8.62 +0.13 (+1.53%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 8:08 AM | americanbankingnews.comTheravance Biopharma, Inc. to Post Q3 2024 Earnings of ($0.18) Per Share, Zacks Research Forecasts (NASDAQ:TBPH)May 29 at 8:10 AM | americanbankingnews.comTheravance Biopharma's (TBPH) "Buy" Rating Reiterated at HC WainwrightMay 28, 2024 | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Downgraded to "Hold" at StockNews.comMay 28, 2024 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Cut to Hold at StockNews.comStockNews.com cut Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Tuesday.May 24, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Theravance Biopharma (TBPH)May 21, 2024 | finance.yahoo.comTheravance Biopharma First Quarter 2024 Earnings: Beats ExpectationsMay 21, 2024 | marketbeat.comStockNews.com Upgrades Theravance Biopharma (NASDAQ:TBPH) to "Buy"StockNews.com raised shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a research report on Monday.May 17, 2024 | markets.businessinsider.comBuy Rating Affirmed on Theravance Biopharma Amid Strong Q1 Performance and Promising Pipeline ProspectsMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Theravance Biopharma on Strong Portfolio Performance and Promising Drug ProspectsMay 14, 2024 | msn.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2024 Earnings Call TranscriptMay 14, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Theravance Biopharma (NASDAQ:TBPH)HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Theravance Biopharma in a research report on Tuesday.May 13, 2024 | investorplace.comTBPH Stock Earnings: Theravance Biopharma Beats EPS, Beats Revenue for Q1 2024May 13, 2024 | msn.comTheravance Biopharma GAAP EPS of -$0.24 beats by $0.01, revenue of $14.51M beats by $0.56MMay 13, 2024 | prnewswire.comTheravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 12, 2024 | markets.businessinsider.comTheravance Biopharma earnings preview: what Wall Street is expectingMay 12, 2024 | msn.comTheravance Biopharma Q1 2024 Earnings PreviewMay 9, 2024 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceMay 6, 2024 | marketbeat.comTheravance Biopharma (TBPH) to Release Earnings on MondayTheravance Biopharma (NASDAQ:TBPH) will be releasing earnings after the market closes on Monday, May 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591386)April 29, 2024 | prnewswire.comTheravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024April 17, 2024 | marketbeat.comZacks Research Analysts Reduce Earnings Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH)Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Stock analysts at Zacks Research lowered their FY2024 EPS estimates for shares of Theravance Biopharma in a report issued on Monday, April 15th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will post earniApril 17, 2024 | msn.comTheravance Biopharma (TBPH) Price Target Increased by 10.00% to 15.71April 16, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) to Post Q1 2026 Earnings of $0.29 Per Share, Zacks Research ForecastsTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Research analysts at Zacks Research upped their Q1 2026 EPS estimates for shares of Theravance Biopharma in a research report issued on Monday, April 15th. Zacks Research analyst K. Shah now expects that the biopharmaceutical company will pApril 15, 2024 | investorplace.comBTIG Research Predicts Over 118% Rally for These 3 StocksApril 12, 2024 | marketbeat.comVanguard Group Inc. Sells 379,627 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)Vanguard Group Inc. trimmed its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 9.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,839,329 shares of the biopharmaceutical compaApril 10, 2024 | finance.yahoo.comTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024April 10, 2024 | prnewswire.comTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024March 26, 2024 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Below Fifty Day Moving Average of $9.04Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Below 50 Day Moving Average of $9.04March 18, 2024 | marketbeat.comEquities Analysts Offer Predictions for Theravance Biopharma, Inc.'s Q1 2024 Earnings (NASDAQ:TBPH)Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Analysts at Zacks Research decreased their Q1 2024 earnings per share (EPS) estimates for shares of Theravance Biopharma in a report issued on Wednesday, March 13th. Zacks Research analyst K. Shah now anticipates that the biopharmaceuticalMarch 15, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Forecasted to Earn FY2026 Earnings of $0.75 Per ShareTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Research analysts at Zacks Research issued their FY2026 earnings per share estimates for shares of Theravance Biopharma in a report issued on Wednesday, March 13th. Zacks Research analyst K. Shah forecasts that the biopharmaceutical companyMarch 15, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $3.52 Million Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Jacobs Levy Equity Management Inc. lessened its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 31.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 407,525March 12, 2024 | investorplace.comShort-Squeeze Showdown: 3 Stocks Ready to Crush the SkepticsMarch 8, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Forecasted to Earn Q1 2024 Earnings of ($0.40) Per ShareTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of Theravance Biopharma in a research note issued on Tuesday, March 5th. Leerink Partnrs analyst D. Risinger anticipates that the bioMarch 7, 2024 | markets.businessinsider.comAnalyst Reiterates Buy Rating with Increased Price Target Amidst Financial Adjustments and Milestone Payment PotentialMarch 7, 2024 | marketbeat.comFY2026 EPS Estimates for Theravance Biopharma, Inc. Raised by Leerink Partnrs (NASDAQ:TBPH)Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2026 earnings per share estimates for Theravance Biopharma in a research note issued on Tuesday, March 5th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceuFebruary 28, 2024 | markets.businessinsider.comTheravance Biopharma: A Strong Buy on Underappreciated Cash Flow Potential and Strategic MilestonesFebruary 28, 2024 | finance.yahoo.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call TranscriptFebruary 27, 2024 | stockhouse.comTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 27, 2024 | investing.comTheravance Biopharma Inc (TBPH)February 27, 2024 | markets.businessinsider.comBalancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance BiopharmaFebruary 26, 2024 | msn.comTheravance Biopharma GAAP EPS of -$0.17 misses by $0.02, revenue of $17.6M beats by $0.03MFebruary 26, 2024 | prnewswire.comTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 25, 2024 | seekingalpha.comTheravance Biopharma Q4 2023 Earnings PreviewFebruary 24, 2024 | benzinga.comTheravance Biopharma Stock (NASDAQ:TBPH) Dividends: History, Yield and DatesFebruary 24, 2024 | msn.comTheravance Biopharma (TBPH) Price Target Increased by 5.77% to 14.03February 22, 2024 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceFebruary 15, 2024 | finance.yahoo.comWill Theravance Biopharma (NASDAQ:TBPH) Spend Its Cash Wisely?February 15, 2024 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Price Passes Below 200-Day Moving Average of $9.83Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Below Two Hundred Day Moving Average of $9.83February 14, 2024 | finance.yahoo.comTheravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024February 14, 2024 | prnewswire.comTheravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024February 1, 2024 | finance.yahoo.comTheravance Biopharma, Inc. (TBPH) Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Crypto That You Don’t Own… Yet (Ad)There’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening. Click here for all the details… TBPH Media Mentions By Week TBPH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TBPH News Sentiment▼0.600.82▲Average Medical News Sentiment TBPH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TBPH Articles This Week▼72▲TBPH Articles Average Week Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ANNX News PLRX News SDGR News ARDX News TARO News EWTX News LGND News MORF News DVAX News GMTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TBPH) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyOn June 10, Nvidia makes its next big moveWeiss RatingsMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…AltimetryUnlock Explosive Gains with This Defense StockBehind the MarketsElon’s Revenge on BidenTradeSmithClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
